PARSIPPANY, N.J. — Watson Pharmaceuticals Inc. has begun shipping morphine sulfate extended-release capsules.
The company said Thursday it has received approval from the Food and Drug Administration for its abbreviated new drug application (ANDA) for the product, a generic equivalent of Actavis’ Kadian.
A narcotic pain reliever, morphine sulfate extended-release capsules are indicated to manage moderate to severe pain lasting around-the-clock and expected to continue over an extended time period.
Kadian had sales of about $275 million for the l2 months ended Sept. 30, according to IMS Health figures reported by Watson.
